Table 1.
Study cohort patients’ characteristics
| Overall (n = 228) | Negative MRI (n = 113) | No MRI (n = 115) | p value | |
|---|---|---|---|---|
| Age, years Mean (SD) |
64.9 (7.3) |
63.7 (7.3) |
65.6 (7.2) |
0.65 |
| PSA, ng/ml Mean (SD) |
7.09 (3.9) |
7.6 (4.0) |
7.4 (3.7) |
0.75 |
| DRE, n (%) Negative Positive |
184 (80.7) 44 (19.3) |
96 (85.0) 17 (15.0) |
88 (76.5) 27 (23.5) |
0.11 |
| Prostate volume, cc Mean (SD) |
86.9 (34.4) |
95.3 (44.8) |
86.6 (44.4) |
0.14 |
| Adenoma volume, cc Mean (SD) |
54.5 (28.4) |
61.9 (36.2) |
52.7 (36.5) |
0.06 |
| PSA Density, ng/ml/cc Mean (SD) |
0.09 (0.06) |
0.09 (0.04) |
0.09 (0.07) |
0.37 |
| PSA Density > 0.15 ng/ml/cc, n (%) No Yes |
192 (84.2) 36 (15.8) |
99 (86.1) 16 (13.9) |
93 (82.3) 20 (17.7) |
0.23 |
| Qmax, mL/sec Median (IQR) |
8.0 (6.7–9.8) |
8.0 (6.7–9.8) |
8.8 (6.1–9.9) |
0.85 |
| IPSS score Median (IQR) |
18.5 (15.75–23) |
18 (17–22) |
19.5 (15–25.5) |
0.84 |
| QoL score Median (IQR) |
4 (3–5) |
4 (3–5) |
4 (3–5) |
0.75 |
| PRV, cc Median (IQR) |
66 (0–189) |
120 (60–320) |
80 (20–130) |
0.02* |
| Drug assumption, n (%) No Alfa blocker 5-ARI 5-ARI + alfa-blocker |
66 (28.9) 68 (29.8) 10 (4.4) 84 (36.9) |
37 (32.7) 32 (28.3) 1 (0.9) 43 (38.1) |
29 (25.2) 36 (31.3) 9 (7.8) 41 (35.7) |
0.07 |
| Previous acute urinary retention, n (%) No Yes |
180 (78.9) 48 (21.1) |
97 (85.8) 16 (14.2) |
83 (72.2) 32 (27.8) |
0.01* |
Continuous variables are shown as mean (SD) and median (IQR) values based on their distribution while categorical as number (%). Statistically significant values are considered as p value <0.05.
PSA – prostate specific antigen; DRE – digital rectal examination; Qmax – maximum peak urinary flow; IPSS – international prostate symptoms score; QoL – quality of life; PRV – post-void volume; 5-ARI – 5-aromatase receptor inhibitor